Philips Expands Imaging Capabilities on Handheld Ultrasound Device
In addition to newly added advances with hemodynamic assessment and obstetric measurements, Lumify also offers a B-line quantification tool and AI-enhanced algorithms that may bolster ultrasound lung imaging in severe COVID-19 cases.
Building upon the applications of its handheld, point-of-care ultrasound device Lumify, Philips noted the modality now features advanced hemodynamic assessment as well as obstetric measurement capabilities.
The addition of Pulse Wave Doppler to Lumify enables clinicians to differentiate between arterial and venous blood flow and quantify hemodynamic function. Philips said the hemodynamic measurement capabilities of Lumify can facilitate timely interventions in cardiology and emergency medicine settings. The use of obstetric measurements may also aid in identifying high-risk pregnancies, according to the company.
“With the addition of Pulse Wave Doppler and enhanced obstetric measurements, we have increased the number of markers on which diagnoses can be made to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real time,” noted Matthijs Groot Wassink, general manager of point of care ultrasound at Philips.
Noting the key role of lung ultrasound in diagnosing pneumonia, a common complication of COVID-19, Philips maintained that Lumify is the only point-of-care ultrasound device that features artificial intelligence (AI)-enhanced B-line quantification. The company said the ability of this technology to assess B-lines in lung fluid may be beneficial for patients with severe cases of COVID-19 infection.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
